Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Betaseron (Interferon Beta-1b) for SC Injection
Predictors of Fatigue Impact in Persons With Long-Standing Multiple Sclerosis.
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
Neuroimmunomodulation by allogeneic seminal vesicle fluid in CNS is sex-independent.
Social Media Representation of Chronic Cerebrospinal Venous Insufficiency Intervention for Multiple Sclerosis.
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology.
Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis.
Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging.
195 How Well Do Neuroradiologists Predict the Side of Trigeminal Neuralgia?
Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis.
Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
You-Gui pills promote nerve regeneration by regulating netrin1, DCC and Rho family GTPases RhoA, Racl, Cdc42 in C57BL/6 mice with experimental autoimmune encephalomyelitis.
Secondary Progressive Multiple Sclerosis: Definition and Measurement.
Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM.
Biogen slips as FDA extends review of MS drug
Disease Modifying Therapies Modulate Cardiovascular Risk Factors in Multiple Sclerosis Patients.
Mutation Analysis of Gap Junction Protein Beta 1 and Genotype-Phenotype Correlation in X-linked Charcot-Marie-Tooth Disease in Chinese Patients.
Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells.
Sema4A inhibits the therapeutic effect of IFN-β in EAE.
Optical Coherence Tomography in Multiple Sclerosis.
CombiRx for MS not better than monotherapy
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.

Pages